{
    "nctId": "NCT04541420",
    "briefTitle": "Eribulin in mTNBC Patients",
    "officialTitle": "An Observational, Retrospective Study of Eribulin in Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 208,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.\n2. Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug 2020.\n3. Available medical history.\n\nExclusion Criteria:\n\n1. Incomplete medical history.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}